Back to top
more

Tonix Pharmaceuticals (TNXP)

(Delayed Data from NSDQ)

$0.16 USD

0.16
2,024,539

+0.01 (6.34%)

Updated Apr 17, 2024 04:00 PM ET

After-Market: $0.16 0.00 (0.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Tonix Pharmaceuticals Holding Corp. [TNXP]

Reports for Purchase

Showing records 121 - 140 ( 154 total )

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 121

06/18/2014

Company Report

Pages: 6

Physician Call Highlights Promise of TNX-102 SL

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 122

06/16/2014

Company Report

Pages: 4

Physician Call (Today - June 16, Noon ET)

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 123

06/16/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 124

06/12/2014

Company Report

Pages: 4

Physician Call (June 16, Noon ET)

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 125

06/12/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 126

05/14/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 127

05/14/2014

Company Report

Pages: 8

1Q14 Recap - Fibromyalgia Data Coming in Early 4Q14

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 128

05/14/2014

Company Report

Pages: 15

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 129

04/16/2014

Company Report

Pages: 3

4Q13 Update

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 130

04/01/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 131

03/31/2014

Company Report

Pages: 15

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 132

03/31/2014

Company Report

Pages: 8

4Q13 Recap - Data Coming in 4Q14

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 133

03/28/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 134

03/28/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 135

03/28/2014

Company Report

Pages: 4

Depressed Valuation, Plus Catalysts, Could Drive Upside

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 136

01/22/2014

Company Report

Pages: 6

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 137

01/10/2014

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 138

01/10/2014

Company Report

Pages: 7

Raising PT to Reflect Lower Dilution and Emergence of Expanded Pipeline

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 139

12/30/2013

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 140

11/26/2013

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party